At the bottom of Sigma Healthcare’s results on Thursday was the line on which Goldman Sachs was available for strategic advice.
Street Talk understands Goldman was one of several banks that approached Australia’s largest pharmaceutical wholesaler and manufacturer over the past two months. The statement notes that Goldman is on the bridge for mergers and acquisitions and strategic advice, but there is no doubt that the mandate will include the potential for defense work and the launch of larger transactions.
This is especially the case given the keen interest in the healthcare sector and related industries in which Sigma operates. Sigma has also built a retail footprint across five brands; Amcal +, Chemist King, Discount Drug Stores, Guardian and PharmaSave.
âWhile we have made some progress with small acquisitions in recent years, this appointment provides the resources and the framework to accelerate the execution of our strategy within our disciplined investment criteria,â said CEO of Sigma, Mark Hooper, in ASX press release.
Last year, the company was in the spotlight after taking legal action against My Chemist / Chemist Warehouse.
The powerful pharmaceutical group said it would start buying drugs from another wholesaler, which Sigma said was in violation of its supply agreement. He has since dropped the lawsuit after the pair agreed to formal negotiations to resolve the dispute.